Drug · DIN 02526271
EVUSHELD
1 VIAL TIXAGEVIMAB 1 VIAL CILGAVIMAB
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since March 27, 2024; first marketed April 19, 2022.
- Drug Identification Number (DIN)
- 02526271
- Company (DIN owner)
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intramuscular
- Therapeutic class (ATC)
- Tixagevimab and cilgavimab J06BD03
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TIXAGEVIMAB | 150 MG | 1.5 ML |
| CILGAVIMAB | 150 MG | 1.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 14, 2022: NOC 27978New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “evusheld”. A notice may cover another product or only some lots: read it to see what it covers.
- EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 SubvariantsJanuary 17, 2023 · Biologic or vaccine · New safety information - Product safety - COVID
- EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral ResistanceOctober 26, 2022 · Biologic or vaccine · New safety information - Product safety - COVID